Description
Midostaurin is used in the treatment of advanced systemic mastocytosis and FLT3-mutated acute myeloid leukemia. It has shown efficacy in combination with chemotherapy for patients with newly diagnosed AML who have an FLT3 mutation, but its use in colorectal cancer (CRC) remains investigational.
Mechanism of Action
Midostaurin inhibits multiple kinases, including protein kinase C (PKC), FMS-like tyrosine kinase 3 (FLT3), and KIT, which are involved in cell proliferation and survival pathways.
Side Effects
Febrile neutropenia; thrombocytopenia; gastrointestinal hemorrhage; hepatotoxicity; cardiac toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT01282502
med_phase_prefix1
Archived
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
United States